Results 81 to 90 of about 225,025 (354)

Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening

Hepatology Communications, EarlyView., 2022
Abstract Health care initiatives, such as hepatitis C virus (HCV) screening, have been greatly overshadowed by the corona virus disease 2019 (COVID‐19) pandemic. However, COVID‐19 vaccination programs also provide an opportunity to engage with a high volume of people in a health care setting.
Aaron Vanderhoff, David Smookler, Mia J. Biondi, Scott Enman, Tintin Fuliang, Sana Mahmood, Agustina Crespi, Maria Marquez, Rafique Van Uum, Lucy You, Brett Wolfson‐Stofko, Renee Logan, Erin LeDrew, Hemant Shah, Harry Janssen, Camelia Capraru, Elisa Venier, Jordan J. Feld   +17 more
wiley   +1 more source

Analysis of pilot data assessing vaccine hesitancy in an urban clinic setting [PDF]

, 2018
Widespread use of childhood vaccination has significantly reduced the burden of childhood disease, however a subset of parents are choosing to delay or refuse available vaccines.
Williams, Amelia
core  

Tailoring Vascular‐Immune Homeostasis via Manganese‐DNA Complex‐Armed Immunogenic Extracellular Vesicles for Pancreatic Cancer Immunotherapy

Advanced Science, EarlyView.
This study demonstrates that Mn2⁺–tumor DNA complexes encapsulated in dendritic cell (DC)– derived immunogenic extracellular vesicles (EVDC@Mn‐DNA) act as a DC‐specific cGAS– STING activator. EVDC@Mn‐DNA treatment enhances intratumoral DC activation, improves tumor vascular function, promotes CD8⁺ T cell activity, and suppresses pancreatic tumor growth,
Xue Jiang, Lihuan Shang, Xiaochun Chen, Xiangzhan Kong, Xiaojuan Wang, Linjia Jiang, Huiying Zhao, Yafeng Zhu, Cheng Huang, Shiyi Deng, Rui Zhang, Minghui Wang, Haoming Lin, Ping‐Pui Wong   +13 more
wiley   +1 more source

An mRNA vaccine candidate encoding cholera toxin subunit B and conserved antigens of influenza viruses confers cross-protection against influenza a viruses in adult and aged mice

Human Vaccines & Immunotherapeutics
Currently, vaccination with influenza vaccines is still an effective strategy to prevent infection by seasonal influenza virus. However, seasonal influenza vaccines frequently fail to induce effective immune protection against rapidly changing seasonal ...
Liang Xu, Zhihao Yu, Yifan Xu, Qin Wang, Guiqin Wang, Benchi Li, Qian Weng, Yongxiang Yi, Junwei Li   +8 more
doaj   +1 more source

ZNRD2 Mediated Nucleoprotein Aggregation Impairs Respiratory Syncytial Virus Replication

Advanced Science, EarlyView.
During RSV infection, nucleoprotein (N) forms RNA‐bound oligomers. The host protein ZNRD2 binds to these oligomers, promoting their transition into insoluble aggregates. These aggregates simultaneously sequester functional N to restrict viral production and disrupt chaperonin assembly quality control by interfering with ZNRD2's role as an adaptor ...
Haiwu Zhou, Mingbin He, Jinhong Du, Cong Liu, Weiwei Wang, Yuewen Han, Zhifei Li, Yali Qin, Mingzhou Chen   +8 more
wiley   +1 more source

Adjuvanted influenza vaccines

Expert Review of Vaccines, 2013
Influenza is one of the most common causes of human morbidity and mortality that is preventable by vaccination. Immunization with available vaccines provides incomplete protection against illness caused by influenza virus, especially in high-risk groups such as the elderly and young children.
Orli, Even-Or, Sarit, Samira, Ronald, Ellis, Eli, Kedar, Yechezkel, Barenholz   +4 more
openaire   +2 more sources

Potent and Long‐Lasting Immunogenicity Generated by LNP‐mRNA gE Antigen Against Varicella Zoster Virus via an AI‐Assisted Pipeline

Advanced Science, EarlyView.
This study designs a novel mRNA‐LNP vaccine targeting VZV glycoprotein E (gE) for herpes zoster via an AI‐assisted pipeline. Validated in mice and rhesus macaques, the mRNA‐LNP vaccine shows strong humoral and cellular immune responses, with CD4+ T‐cell responses more effective and durable than Shingrix, offering a promising prophylactic option ...
Kai Dong, Fang Liu, Dawei Wang, Yanfen Li, Man Zhang, Yuting Zhou, Gengshen Song   +6 more
wiley   +1 more source

Nonreplicating Influenza A Virus Vaccines Confer Broad Protection against Lethal Challenge

mBio, 2015
New vaccine technologies are being investigated for their ability to elicit broadly cross-protective immunity against a range of influenza viruses. We compared the efficacies of two intranasally delivered nonreplicating influenza virus vaccines (H1 and ...
Mariana Baz, Kobporn Boonnak, Myeisha Paskel, Celia Santos, Timothy Powell, Alain Townsend, Kanta Subbarao   +6 more
doaj   +1 more source

Prospects and Challenges in the Development of Universal Influenza Vaccines

Vaccines, 2020
Current influenza vaccines offer suboptimal protection and depend on annual reformulation and yearly administration. Vaccine technology has rapidly advanced during the last decade, facilitating development of next-generation influenza vaccines that can ...
Anders Madsen, Rebecca Jane Cox
doaj   +1 more source

Nanoparticle Adjuvant Design Enhances Germinal Center Responses Targeting Conserved Subdominant Epitopes for Pan‐Coronavirus Vaccine Development

Advanced Science, EarlyView.
Current SARS‐CoV‐2 vaccines generate short‐lived, strain‐specific immunity. A polymeric TLR7 agonist nanoparticle (TLR7‐NP) adjuvant enhances lymph node targeting and promotes early and sustained germinal center responses toward conserved S2 epitopes of the spike protein.
Sijin Huang, Kanella M. Cohen, Liqiang Chen, Xiaowo Kang, Chang Liu, Megan E. Demouth, Wenxia Jiang, Alexander R. Maldeney, Rong Tong, Zunlong Ke, Kartik Chandran, Wei Luo, Qian Yin   +12 more
wiley   +1 more source